{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:02:55Z","timestamp":1773860575797,"version":"3.50.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100011866","name":"Colorado Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","award":["UL1TR002535"],"award-info":[{"award-number":["UL1TR002535"]}],"id":[{"id":"10.13039\/100011866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with burn injuries are at high risk for infection as well as altered antimicrobial pharmacokinetics. Patients suffering from a burn injury, generally encompassing a total body surface area (TBSA) \u2265 20%, have been cited as at risk for augmented renal clearance (ARC). Our case report describes an obese patient with 3.2% TBSA partial thickness burns who suffered from burn wound cellulitis with Pseudomonas aeruginosa. Measured CLcr documented the presence of ARC, and 22.5 grams daily continuous infusion of piperacillin-tazobactam was initiated. Therapeutic monitoring of piperacillin at steady state was 78 mcg\/mL, achieving the prespecified goal piperacillin concentration of 100% 4-times the minimum inhibitory concentration assuming MIC for susceptible P. aeruginosa at 16\/4 mcg\/mL per Clinical Laboratory Standards Institute. Available literature suggests younger critically ill patients with lower organ failure scores, and for a burn injury, a higher percentage of TBSA, are most likely to exhibit ARC which does not entirely align with the characteristics of our patient. In addition, piperacillin-tazobactam has been associated with altered pharmacokinetics in ARC, burn, and obese populations, demonstrating failure to meet target attainment with standard doses. We suggest a continuous infusion of piperacillin-tazobactam be used when ARC is identified. This case report describes the unique findings of ARC in a non-critically ill burn patient and rationalizes the need for further prospective research to classify incidence, risk factors, and appropriate antimicrobial regimens for burn patients with ARC.<\/jats:p>","DOI":"10.1093\/jbcr\/irac138","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T16:28:31Z","timestamp":1664468911000},"page":"203-206","source":"Crossref","is-referenced-by-count":7,"title":["Burn Injury and Augmented Renal Clearance: A Case for Optimized Piperacillin-Tazobactam Dosing"],"prefix":"10.1093","volume":"44","author":[{"given":"Sterling C","family":"Torian","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, 12850 E Montview Blvd , Aurora, Colorodo 80045 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arek J","family":"Wiktor","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of GI, Trauma, and Endocrine Surgery (GITES), University of Colorado Hospital, 12631 East 17th Ave , Suite 6111, Aurora, Colorodo 80045 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara E","family":"Roper","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of GI, Trauma, and Endocrine Surgery (GITES), University of Colorado Hospital, 12631 East 17th Ave , Suite 6111, Aurora, Colorodo 80045 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate E","family":"Laramie","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of GI, Trauma, and Endocrine Surgery (GITES), University of Colorado Hospital, 12631 East 17th Ave , Suite 6111, Aurora, Colorodo 80045 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, 12850 E Montview Blvd , Aurora, Colorodo 80045 , USA"},{"name":"Department of Pharmacy, University of Colorado Hospital, 12605 E 16th Ave , Aurora, CO 80045 , USA"},{"name":"Department of Infectious Diseases, Division of Medicine, University of Colorado Denver School of Medicine, 1635 Aurora Ct. , Aurora, Colorodo 80045 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1238-8199","authenticated-orcid":false,"given":"Scott W","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, 12850 E Montview Blvd , Aurora, Colorodo 80045 , USA"},{"name":"Department of Pharmacy, University of Colorado Hospital, 12605 E 16th Ave , Aurora, CO 80045 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"2023010803175138200_CIT0001","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(16)31469-6","article-title":"The metabolic stress response to burn trauma: current understanding and therapies","volume":"388","author":"Porter","year":"2016","journal-title":"Lancet"},{"key":"2023010803175138200_CIT0002","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1097\/BCR.0000000000000355","article-title":"Burns","volume":"38","author":"Nielson","year":"2017","journal-title":"J Burn Care Res"},{"key":"2023010803175138200_CIT0003","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/phar.2231","article-title":"Augmented renal clearance","volume":"39","author":"Cook","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2023010803175138200_CIT0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11318140-000000000-00000","article-title":"Augmented renal clearance","volume":"49","author":"Udy","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"2023010803175138200_CIT0005","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/AAC.34.5.792","article-title":"Vancomycin pharmacokinetics in burn patients and intravenous drug abusers","volume":"34","author":"Rybak","year":"1990","journal-title":"Antimicrob Agents and Chemother"},{"key":"2023010803175138200_CIT0006","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1128\/AAC.40.1.139","article-title":"Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection","volume":"40","author":"Bourget","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010803175138200_CIT0007","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2125.2006.02807.x","article-title":"Assessment of renal function in clinical practice at the bedside of burn patients","volume":"63","author":"Conil","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"2023010803175138200_CIT0008","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current -lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023010803175138200_CIT0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"20 2014","journal-title":"Adv Drug Deliv Rev"},{"key":"2023010803175138200_CIT0010","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJM197810262991703","article-title":"Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin","volume":"299","author":"Loirat","year":"1978","journal-title":"N Engl J Med"},{"key":"2023010803175138200_CIT0011","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1128\/AAC.02089-13","article-title":"Population pharmacokinetic analysis of piperacillin in burn patients","volume":"58","author":"Jeon","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010803175138200_CIT0012","first-page":"262","article-title":"Pharmacokinetic evaluation of continuous and extended-infusion antibiotics in burn patients","volume":"44","author":"Paavola","year":"2016","journal-title":"Crit Care"},{"key":"2023010803175138200_CIT0013","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00210-018-1573-6","article-title":"After standard dosage of piperacillin plasma concentrations of drug are subtherapeutic in burn patients","volume":"392","author":"Olbrisch","year":"2019","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"2023010803175138200_CIT0014","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcrc.2018.08.026","article-title":"Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion","volume":"48","author":"Carri\u00e9","year":"2018","journal-title":"J Crit Care"},{"key":"2023010803175138200_CIT0015","author":"Performance Standards for Antimicrobial Susceptibility Testing."},{"key":"2023010803175138200_CIT0016","author":"The European Committee on Antimicrobial Susceptibility Testing - EUCAST."},{"key":"2023010803175138200_CIT0017","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/phar.1653","article-title":"Implications of augmented renal clearance on drug dosing in critically ill patients: a focus on antibiotics","volume":"35","author":"Hobbs","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2023010803175138200_CIT0018","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13054-015-0750-y","article-title":"Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?","volume":"19","author":"Udy","year":"2015","journal-title":"Crit Care"}],"container-title":["Journal of Burn Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/irac138\/46496381\/irac138.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/irac138\/48514591\/irac138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/irac138\/48514591\/irac138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T03:18:37Z","timestamp":1673147917000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbcr\/article\/44\/1\/203\/6731011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,9,29]]},"published-print":{"date-parts":[[2023,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jbcr\/irac138","relation":{},"ISSN":["1559-047X","1559-0488"],"issn-type":[{"value":"1559-047X","type":"print"},{"value":"1559-0488","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,9,29]]}}}